Strategically modified hepatitis B core proteins and their derivatives
US6231864A · kind A · utility
54Cited by
4References
22Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 11, 1999 |
| Grant date | May 15, 2001 |
| Priority date | — |
| Expiry date | Feb 11, 2019 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/917
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A strategically modified hepatitis B core protein is described, where an insert is provided, preferably in an immunodominant region of the nucleocapsid protein, containing a chemically reactive amino acid residue. The modified hepatitis B core protein or its aggregated nucleocapsid protein particles can be pendently linked to a hapten to form a modified nucleocapsid conjugate. Such a conjugate is useful in the preparation of vaccines or antibodies. The modified hepatitis B core protein can also be modified to include a T cell epitope.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.